vs
Side-by-side financial comparison of Dream Finders Homes, Inc. (DFH) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
Dream Finders Homes, Inc. is the larger business by last-quarter revenue ($1.2B vs $622.0M, roughly 1.9× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs 4.8%, a 29.6% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs -22.3%). Over the past eight quarters, Dream Finders Homes, Inc.'s revenue compounded faster (21.0% CAGR vs 4.6%).
Dream Finders Homes, Inc. is a U.S. homebuilding firm that constructs and sells entry-level to luxury residential properties, including single-family homes and townhomes, across high-growth domestic markets. It also provides mortgage, title insurance and home warranty services for homebuyers.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
DFH vs RPRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $622.0M |
| Net Profit | $58.8M | $214.2M |
| Gross Margin | — | — |
| Operating Margin | 6.4% | 62.4% |
| Net Margin | 4.8% | 34.4% |
| Revenue YoY | -22.3% | 4.8% |
| Net Profit YoY | -54.9% | 2.9% |
| EPS (diluted) | $0.57 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2B | $622.0M | ||
| Q3 25 | $969.8M | $609.3M | ||
| Q2 25 | $1.2B | $578.7M | ||
| Q1 25 | $989.9M | $568.2M | ||
| Q4 24 | $1.6B | $593.6M | ||
| Q3 24 | $1.0B | $564.7M | ||
| Q2 24 | $1.1B | $537.3M | ||
| Q1 24 | $827.8M | $568.0M |
| Q4 25 | $58.8M | $214.2M | ||
| Q3 25 | $47.0M | $288.2M | ||
| Q2 25 | $56.6M | $30.2M | ||
| Q1 25 | $54.9M | $238.3M | ||
| Q4 24 | $130.5M | $208.2M | ||
| Q3 24 | $70.7M | $544.0M | ||
| Q2 24 | $80.9M | $102.0M | ||
| Q1 24 | $54.5M | $4.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 19.2% | — | ||
| Q1 24 | 18.0% | — |
| Q4 25 | 6.4% | 62.4% | ||
| Q3 25 | 6.3% | 70.1% | ||
| Q2 25 | 6.4% | 36.3% | ||
| Q1 25 | 7.2% | 94.0% | ||
| Q4 24 | 10.8% | 60.9% | ||
| Q3 24 | 9.2% | — | ||
| Q2 24 | 10.0% | 50.2% | ||
| Q1 24 | 8.6% | -13.0% |
| Q4 25 | 4.8% | 34.4% | ||
| Q3 25 | 4.8% | 47.3% | ||
| Q2 25 | 4.9% | 5.2% | ||
| Q1 25 | 5.5% | 41.9% | ||
| Q4 24 | 8.4% | 35.1% | ||
| Q3 24 | 7.0% | 96.3% | ||
| Q2 24 | 7.7% | 19.0% | ||
| Q1 24 | 6.6% | 0.8% |
| Q4 25 | $0.57 | $0.49 | ||
| Q3 25 | $0.47 | $0.67 | ||
| Q2 25 | $0.56 | $0.07 | ||
| Q1 25 | $0.54 | $0.55 | ||
| Q4 24 | $1.28 | $0.46 | ||
| Q3 24 | $0.70 | $1.21 | ||
| Q2 24 | $0.81 | $0.23 | ||
| Q1 24 | $0.55 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $234.8M | $618.7M |
| Total DebtLower is stronger | $1.6B | $9.0B |
| Stockholders' EquityBook value | $1.4B | $9.7B |
| Total Assets | $3.7B | $19.6B |
| Debt / EquityLower = less leverage | 1.13× | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $234.8M | $618.7M | ||
| Q3 25 | $251.0M | $938.9M | ||
| Q2 25 | $210.3M | $631.9M | ||
| Q1 25 | $297.5M | $1.1B | ||
| Q4 24 | $274.4M | $929.0M | ||
| Q3 24 | $204.9M | $950.1M | ||
| Q2 24 | $274.8M | $1.8B | ||
| Q1 24 | $239.4M | $843.0M |
| Q4 25 | $1.6B | $9.0B | ||
| Q3 25 | $1.8B | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | $1.3B | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
| Q4 25 | $1.4B | $9.7B | ||
| Q3 25 | $1.4B | $9.6B | ||
| Q2 25 | $1.3B | $9.5B | ||
| Q1 25 | $1.3B | $9.8B | ||
| Q4 24 | $1.2B | $10.3B | ||
| Q3 24 | $1.1B | $10.3B | ||
| Q2 24 | $1.0B | $9.8B | ||
| Q1 24 | $968.7M | $9.9B |
| Q4 25 | $3.7B | $19.6B | ||
| Q3 25 | $3.8B | $19.3B | ||
| Q2 25 | $3.7B | $18.3B | ||
| Q1 25 | $3.5B | $17.6B | ||
| Q4 24 | $3.3B | $18.2B | ||
| Q3 24 | $3.3B | $18.0B | ||
| Q2 24 | $3.0B | $17.7B | ||
| Q1 24 | $2.7B | $16.1B |
| Q4 25 | 1.13× | 0.92× | ||
| Q3 25 | 1.29× | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | 1.03× | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $143.6M | $827.1M |
| Free Cash FlowOCF − Capex | $136.0M | — |
| FCF MarginFCF / Revenue | 11.2% | — |
| Capex IntensityCapex / Revenue | 0.6% | — |
| Cash ConversionOCF / Net Profit | 2.44× | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | $-126.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $143.6M | $827.1M | ||
| Q3 25 | $-131.0M | $702.6M | ||
| Q2 25 | $-68.5M | $364.0M | ||
| Q1 25 | $-44.7M | $596.1M | ||
| Q4 24 | $306.5M | $742.5M | ||
| Q3 24 | $-205.0M | $703.6M | ||
| Q2 24 | $-110.6M | $658.2M | ||
| Q1 24 | $-247.5M | $664.6M |
| Q4 25 | $136.0M | — | ||
| Q3 25 | $-135.7M | — | ||
| Q2 25 | $-78.8M | — | ||
| Q1 25 | $-47.9M | — | ||
| Q4 24 | $302.6M | — | ||
| Q3 24 | $-222.5M | — | ||
| Q2 24 | $-112.4M | — | ||
| Q1 24 | $-249.6M | — |
| Q4 25 | 11.2% | — | ||
| Q3 25 | -14.0% | — | ||
| Q2 25 | -6.8% | — | ||
| Q1 25 | -4.8% | — | ||
| Q4 24 | 19.4% | — | ||
| Q3 24 | -22.1% | — | ||
| Q2 24 | -10.6% | — | ||
| Q1 24 | -30.2% | — |
| Q4 25 | 0.6% | — | ||
| Q3 25 | 0.5% | — | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 0.2% | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | 2.44× | 3.86× | ||
| Q3 25 | -2.79× | 2.44× | ||
| Q2 25 | -1.21× | 12.06× | ||
| Q1 25 | -0.81× | 2.50× | ||
| Q4 24 | 2.35× | 3.57× | ||
| Q3 24 | -2.90× | 1.29× | ||
| Q2 24 | -1.37× | 6.45× | ||
| Q1 24 | -4.54× | 139.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DFH
| Midwest Segment | $454.2M | 37% |
| Southeast Segment | $397.5M | 33% |
| Mid Atlantic Segment | $307.3M | 25% |
| Financial Services Segment | $53.7M | 4% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
